Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 235

1.

Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy.

Myers RP, Benhamou Y, Bochet M, Thibault V, Mehri D, Poynard T.

AIDS. 2004 Jan 2;18(1):75-9.

PMID:
15090832
2.

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.

3.

Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients.

Dominguez S, Ghosn J, Valantin MA, Schruniger A, Simon A, Bonnard P, Caumes E, Pialoux G, Benhamou Y, Thibault V, Katlama C.

AIDS. 2006 May 12;20(8):1157-61. Review.

PMID:
16691067
4.

Treatment of chronic hepatitis C in southern Taiwan.

Chuang WL, Yu ML, Dai CY, Chang WY.

Intervirology. 2006;49(1-2):99-106. Review.

PMID:
16166797
6.

Clinical trial results of peginterferons in combination with ribavirin.

Craxi A, Licata A.

Semin Liver Dis. 2003;23 Suppl 1:35-46. Review.

PMID:
12934167
7.

Consensus guidelines for the management of hepatitis C infection.

Consensus Guidelines Committee for the Management of Hepatitis C Infection.

Saudi Med J. 2003 Jul;24 Suppl 2:S99-118.

PMID:
25121186
8.

Current treatment for chronic hepatitis C virus/HIV-infected individuals: the role of pegylated interferon-alpha and ribavirin.

Bhagani S.

Curr Opin HIV AIDS. 2011 Nov;6(6):483-90. doi: 10.1097/COH.0b013e32834bd257. Review.

PMID:
22001893
9.

Pegylated interferon-α2a and ribavirin versus pegylated interferon-α2b and ribavirin in chronic hepatitis C : a meta-analysis.

Flori N, Funakoshi N, Duny Y, Valats JC, Bismuth M, Christophorou D, Daurès JP, Blanc P.

Drugs. 2013 Mar;73(3):263-77. doi: 10.1007/s40265-013-0027-1. Review.

PMID:
23436591
10.

Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms.

Gordon CE, Uhlig K, Lau J, Schmid CH, Levey AS, Wong JB.

Am J Kidney Dis. 2008 Feb;51(2):263-77. doi: 10.1053/j.ajkd.2007.11.003. Review.

PMID:
18215704
11.

Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus.

Iorio A, Marchesini E, Awad T, Gluud LL.

Cochrane Database Syst Rev. 2010 Jan 20;(1):CD004888. doi: 10.1002/14651858.CD004888.pub2. Review.

PMID:
20091566
12.

[Chronic hepatitis C--patients "difficult to treat"].

Pawłowska M, Halota W.

Przegl Epidemiol. 2006;60(1):109-13. Review. Polish.

PMID:
16758748
13.

How to optimize HCV therapy in genotype 2 patients.

Grassi E, Aghemo A.

Liver Int. 2013 Feb;33 Suppl 1:35-40. doi: 10.1111/liv.12056. Review.

PMID:
23286844
14.

Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin.

Asselah T, Estrabaud E, Bieche I, Lapalus M, De Muynck S, Vidaud M, Saadoun D, Soumelis V, Marcellin P.

Liver Int. 2010 Oct;30(9):1259-69. doi: 10.1111/j.1478-3231.2010.02283.x. Review.

15.
16.

Triple therapy with telaprevir: results in hepatitis C virus-genotype 1 infected relapsers and non-responders.

Forestier N, Zeuzem S.

Liver Int. 2012 Feb;32 Suppl 1:44-50. doi: 10.1111/j.1478-3231.2011.02720.x. Review.

PMID:
22212571
17.

[Safety and efficacy of telaprevir in patients with HIV and hepatitis C virus coinfection].

Macías J, Rivero A.

Enferm Infecc Microbiol Clin. 2013 Jul;31 Suppl 3:33-6. doi: 10.1016/S0213-005X(13)70122-8. Review. Spanish.

PMID:
24063901
19.

Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C.

Foote BS, Spooner LM, Belliveau PP.

Ann Pharmacother. 2011 Sep;45(9):1085-93. doi: 10.1345/aph.1P744. Epub 2011 Aug 9. Review.

PMID:
21828346
20.

Supplemental Content

Support Center